Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Peter Ratcliffe shares the prize with William Kaelin of the Dana-Farber Cancer Institute and Gregg Semenza of John Hopkins University for their research on cellular responses to hypoxia.

Peter RatcliffeThe 2019 Nobel Prize for physiology or medicine was announced on Monday 7th October. This year’s award is for the discovery of how cells sense and adapt to varying oxygen levels, a cellular process with underlying implications in multiple diseases including cancer.

Sir Peter is a full member of the Ludwig Institute for Cancer Research Oxford Branch, Director of the Target Discovery Institute in Oxford and Clinical Research Director at the Francis Crick Institute in London. You can read more about Peter Ratcliffe's career and research in the Ludwig Research Highlights report here.


Please see the Oxford University press release or contact the Oxford News Office (+44 1865 280528 or for more information.

Similar stories

Developmental origins of inherited cancers bearing mutations in the oxygen-sensing pathway

Dr Tammie Bishop’s and Professor Sir Peter Ratcliffe’s groups shed light on the developmental origins of inherited cancers with mutations in the HIF pathway.

HIFs inhibit SARS-CoV-2 infection of lung epithelial cells

Activation of hypoxia inducible factors (HIFs) by either hypoxia or drug treatment inhibits SARS-CoV-2 entry and replication in lung epithelial cells, raising the potential of using clinically licensed HIF activators to prevent and/or treat COVID-19.